Follow the people · Insider
Richard A. Heyman
Richard A. Heyman files insider transactions with the SEC as a director of Oric Pharmaceuticals (ORIC). We hold 7 disclosed purchases and sales filed since 23 August 2013, 2 of them in the last 90 days.
- Files forORIC
- Disclosed buys and sells7 in all, 2 in the last 90 days
- Last disclosure28 July 2026
Positions held
9 posts we hold — a term names its own dates; a run of filings only says when they filed- Filed 23 April 2020 — 24 July 2026Director · Oric Pharmaceuticals (ORIC)39 Form 4 lines · source: SEC Form 4
- Filed 23 February 2023 — 17 February 2026Director · Enliven Therapeutics (ELVN)49 Form 4 lines · source: SEC Form 4
- Filed 11 November 2020 — 5 June 2025Director · PMV Pharmaceuticals (PMVP)22 Form 4 lines · source: SEC Form 4
- Filed 26 February 2024 — 26 February 2024Director · RayzeBio (RYZB)1 Form 4 line · source: SEC Form 4
- Filed 19 June 2019 — 17 June 2022Director · Gritstone bio (GRTS)4 Form 4 lines · source: SEC Form 4
- Filed 24 May 2021 — 18 May 2022Director · Metacrine (MTCR)2 Form 4 lines · source: SEC Form 4
- Filed 22 December 2020 — 2 June 2021Director · Yumanity Therapeutics (YMTX)4 Form 4 lines · source: SEC Form 4
- Filed 28 July 2014 — 27 August 2015Director · Receptos (RCPT)4 Form 4 lines · source: SEC Form 4
- Filed 21 August 2013 — 20 August 2015Director · Organovo Holdings (ONVO)4 Form 4 lines · source: SEC Form 4
Everything they disclosed
120 entries, newest first — one per disclosure report, one per Form 4 line- exercised options over 3,500 shares of Oric PharmaceuticalsSEC Form 428 July 2026Common Stock · traded 24 July 2026 · filed 28 July 2026
- ▼ sold on the open market 7,000 shares of Oric PharmaceuticalsSEC Form 428 July 2026Common Stock · traded 24 July 2026 · filed 28 July 2026
- ▼ sold on the open market 6,100 shares of Oric PharmaceuticalsSEC Form 428 July 2026Common Stock · traded 24 July 2026 · filed 28 July 2026
- exercised options over 3,500 shares of Oric Pharmaceuticals (a derivative holding)SEC Form 428 July 2026Stock Option (right to buy) · traded 24 July 2026 · filed 28 July 2026
- ▼ sold on the open market 300 shares of Oric PharmaceuticalsSEC Form 48 July 2026Common Stock · traded 6 July 2026 · filed 8 July 2026
- ▼ sold on the open market 1,230 shares of Enliven TherapeuticsSEC Form 419 February 2026Common Stock · traded 17 February 2026 · filed 19 February 2026
- ▼ sold on the open market 1,230 shares of Enliven TherapeuticsSEC Form 419 February 2026Common Stock · traded 17 February 2026 · filed 19 February 2026
- was granted 19,234 shares of Enliven Therapeutics (a derivative holding)SEC Form 417 February 2026Stock Option (right to buy) · traded 12 February 2026 · filed 17 February 2026
- was granted 19,234 shares of Enliven Therapeutics (a derivative holding)SEC Form 417 February 2026Stock Option (right to buy) · traded 12 February 2026 · filed 17 February 2026
- ▼ sold on the open market 512 shares of Enliven TherapeuticsSEC Form 422 January 2026Common Stock · traded 20 January 2026 · filed 22 January 2026
- ▼ sold on the open market 718 shares of Enliven TherapeuticsSEC Form 422 January 2026Common Stock · traded 20 January 2026 · filed 22 January 2026
- ▼ sold on the open market 512 shares of Enliven TherapeuticsSEC Form 422 January 2026Common Stock · traded 20 January 2026 · filed 22 January 2026
- ▼ sold on the open market 718 shares of Enliven TherapeuticsSEC Form 422 January 2026Common Stock · traded 20 January 2026 · filed 22 January 2026
- ▼ sold on the open market 3,500 shares of Oric PharmaceuticalsSEC Form 420 January 2026Common Stock · traded 16 January 2026 · filed 20 January 2026
- ▼ sold on the open market 3,200 shares of Oric PharmaceuticalsSEC Form 420 January 2026Common Stock · traded 16 January 2026 · filed 20 January 2026
- ▼ sold on the open market 3,500 shares of Oric PharmaceuticalsSEC Form 420 January 2026Common Stock · traded 16 January 2026 · filed 20 January 2026
- ▼ sold on the open market 3,200 shares of Oric PharmaceuticalsSEC Form 420 January 2026Common Stock · traded 16 January 2026 · filed 20 January 2026
- ▼ sold on the open market 1,620 shares of Enliven TherapeuticsSEC Form 412 January 2026Common Stock · traded 8 January 2026 · filed 12 January 2026
- ▼ sold on the open market 8,015 shares of Enliven TherapeuticsSEC Form 412 January 2026Common Stock · traded 8 January 2026 · filed 12 January 2026
- ▼ sold on the open market 4,285 shares of Enliven TherapeuticsSEC Form 412 January 2026Common Stock · traded 9 January 2026 · filed 12 January 2026
- ▼ sold on the open market 1,620 shares of Enliven TherapeuticsSEC Form 412 January 2026Common Stock · traded 8 January 2026 · filed 12 January 2026
- ▼ sold on the open market 8,015 shares of Enliven TherapeuticsSEC Form 412 January 2026Common Stock · traded 8 January 2026 · filed 12 January 2026
- ▼ sold on the open market 4,285 shares of Enliven TherapeuticsSEC Form 412 January 2026Common Stock · traded 9 January 2026 · filed 12 January 2026
- was granted 40,000 shares of Oric Pharmaceuticals (a derivative holding)SEC Form 46 January 2026Stock Option (right to buy) · traded 2 January 2026 · filed 6 January 2026
- was granted 40,000 shares of Oric Pharmaceuticals (a derivative holding)SEC Form 46 January 2026Stock Option (right to buy) · traded 2 January 2026 · filed 6 January 2026
- exercised options over 13,228 shares of Oric Pharmaceuticals (a derivative holding)SEC Form 43 October 2025Stock Option (right to buy) · traded 3 October 2025 · filed 3 October 2025
- exercised options over 18,125 shares of Oric Pharmaceuticals (a derivative holding)SEC Form 43 October 2025Stock Option (right to buy) · traded 3 October 2025 · filed 3 October 2025
- exercised options over 1,447 shares of Oric Pharmaceuticals (a derivative holding)SEC Form 43 October 2025Stock Option (right to buy) · traded 3 October 2025 · filed 3 October 2025
- exercised options over 31,353 shares of Oric PharmaceuticalsSEC Form 43 October 2025Common Stock · traded 3 October 2025 · filed 3 October 2025
- exercised options over 1,447 shares of Oric PharmaceuticalsSEC Form 43 October 2025Common Stock · traded 3 October 2025 · filed 3 October 2025
- was granted 33,500 shares of PMV Pharmaceuticals (a derivative holding)SEC Form 49 June 2025Stock Option (right to buy) · traded 5 June 2025 · filed 9 June 2025
- was granted 23,014 shares of Enliven Therapeutics (a derivative holding)SEC Form 410 February 2025Stock Option (right to buy) · traded 6 February 2025 · filed 10 February 2025
- was granted 35,000 shares of Oric Pharmaceuticals (a derivative holding)SEC Form 46 January 2025Stock Option (right to buy) · traded 2 January 2025 · filed 6 January 2025
- ▼ sold on the open market 817 shares of Enliven TherapeuticsSEC Form 422 October 2024Common Stock · traded 18 October 2024 · filed 22 October 2024
- ▼ sold on the open market 753 shares of Enliven TherapeuticsSEC Form 422 October 2024Common Stock · traded 18 October 2024 · filed 22 October 2024
- ▼ sold on the open market 1,270 shares of Enliven TherapeuticsSEC Form 417 October 2024Common Stock · traded 15 October 2024 · filed 17 October 2024
- ▼ sold on the open market 2,825 shares of Enliven TherapeuticsSEC Form 48 October 2024Common Stock · traded 4 October 2024 · filed 8 October 2024
- ▼ sold on the open market 518 shares of Enliven TherapeuticsSEC Form 43 October 2024Common Stock · traded 1 October 2024 · filed 3 October 2024
- ▼ sold on the open market 1,270 shares of Enliven TherapeuticsSEC Form 418 September 2024Common Stock · traded 16 September 2024 · filed 18 September 2024
- ▼ sold on the open market 650 shares of Enliven TherapeuticsSEC Form 419 August 2024Common Stock · traded 15 August 2024 · filed 19 August 2024
- ▼ sold on the open market 620 shares of Enliven TherapeuticsSEC Form 419 August 2024Common Stock · traded 15 August 2024 · filed 19 August 2024
- ▼ sold on the open market 1,702 shares of Enliven TherapeuticsSEC Form 42 August 2024Common Stock · traded 31 July 2024 · filed 2 August 2024
- ▼ sold on the open market 649 shares of Enliven TherapeuticsSEC Form 42 August 2024Common Stock · traded 31 July 2024 · filed 2 August 2024
- ▼ sold on the open market 1,270 shares of Enliven TherapeuticsSEC Form 417 July 2024Common Stock · traded 15 July 2024 · filed 17 July 2024
- ▼ sold on the open market 1,270 shares of Enliven TherapeuticsSEC Form 420 June 2024Common Stock · traded 17 June 2024 · filed 20 June 2024
- was granted 25,600 shares of Oric Pharmaceuticals (a derivative holding)SEC Form 414 June 2024Stock Option (right to buy) · traded 12 June 2024 · filed 14 June 2024
- was granted 67,500 shares of PMV Pharmaceuticals (a derivative holding)SEC Form 410 June 2024Stock Option (right to buy) · traded 6 June 2024 · filed 10 June 2024
- ▼ sold on the open market 1,270 shares of Enliven TherapeuticsSEC Form 420 May 2024Common Stock · traded 16 May 2024 · filed 20 May 2024
- ▼ sold on the open market 5,045 shares of Enliven TherapeuticsSEC Form 415 April 2024Common Stock · traded 11 April 2024 · filed 15 April 2024
- ▼ sold on the open market 1,190 shares of Enliven TherapeuticsSEC Form 415 April 2024Common Stock · traded 15 April 2024 · filed 15 April 2024
- ▼ sold on the open market 80 shares of Enliven TherapeuticsSEC Form 415 April 2024Common Stock · traded 15 April 2024 · filed 15 April 2024
- ▼ sold on the open market 649 shares of Enliven TherapeuticsSEC Form 415 April 2024Common Stock · traded 11 April 2024 · filed 15 April 2024
- ▼ sold on the open market 1,270 shares of Enliven TherapeuticsSEC Form 421 March 2024Common Stock · traded 19 March 2024 · filed 21 March 2024
- returned to the issuer 367,446 shares of RayzeBioSEC Form 427 February 2024Common Stock · traded 26 February 2024 · filed 27 February 2024
- was granted 29,205 shares of Enliven Therapeutics (a derivative holding)SEC Form 420 February 2024Stock Option (right to buy) · traded 13 February 2024 · filed 20 February 2024
- ▼ sold on the open market 1,270 shares of Enliven TherapeuticsSEC Form 420 February 2024Common Stock · traded 15 February 2024 · filed 20 February 2024
- was granted 21,043 shares of Enliven Therapeutics (a derivative holding)SEC Form 415 February 2024Stock Option (right to buy) · traded 13 February 2024 · filed 15 February 2024
- ▼ sold on the open market 1,270 shares of Enliven TherapeuticsSEC Form 41 February 2024Common Stock · traded 30 January 2024 · filed 1 February 2024
- ▼ sold on the open market 7 shares of Enliven TherapeuticsSEC Form 426 December 2023Common Stock · traded 21 December 2023 · filed 26 December 2023
- ▼ sold on the open market 6 shares of Enliven TherapeuticsSEC Form 426 December 2023Common Stock · traded 21 December 2023 · filed 26 December 2023
- ▼ sold on the open market 168 shares of Enliven TherapeuticsSEC Form 426 December 2023Common Stock · traded 22 December 2023 · filed 26 December 2023
- ▼ sold on the open market 35 shares of Enliven TherapeuticsSEC Form 426 December 2023Common Stock · traded 22 December 2023 · filed 26 December 2023
- ▼ sold on the open market 255 shares of Enliven TherapeuticsSEC Form 421 December 2023Common Stock · traded 19 December 2023 · filed 21 December 2023
- ▼ sold on the open market 2,110 shares of Enliven TherapeuticsSEC Form 421 December 2023Common Stock · traded 20 December 2023 · filed 21 December 2023
- ▼ sold on the open market 1,915 shares of Enliven TherapeuticsSEC Form 421 December 2023Common Stock · traded 20 December 2023 · filed 21 December 2023
- was granted 20,500 shares of Oric Pharmaceuticals (a derivative holding)SEC Form 415 June 2023Stock Option (right to buy) · traded 14 June 2023 · filed 15 June 2023
- was granted 21,500 shares of PMV Pharmaceuticals (a derivative holding)SEC Form 412 June 2023Stock Option (right to buy) · traded 8 June 2023 · filed 12 June 2023
- was granted 34,458 shares of Enliven Therapeutics (a derivative holding)SEC Form 46 April 2023Stock Option (right to buy) · traded 23 February 2023 · filed 6 April 2023
- was granted 20,657 shares of Enliven Therapeutics (a derivative holding)SEC Form 427 February 2023Employee Stock Option (right to buy) · traded 23 February 2023 · filed 27 February 2023
- was granted 149,820 shares of Enliven TherapeuticsSEC Form 427 February 2023Common Stock · traded 23 February 2023 · filed 27 February 2023
- was granted 37,407 shares of Enliven TherapeuticsSEC Form 427 February 2023Common Stock · traded 23 February 2023 · filed 27 February 2023
- was granted 31,172 shares of Enliven TherapeuticsSEC Form 427 February 2023Common Stock · traded 23 February 2023 · filed 27 February 2023
- was granted 16,500 shares of Metacrine (a derivative holding)SEC Form 46 September 2022Stock Option (right to buy) · traded 18 May 2022 · filed 6 September 2022
- was granted 19,000 shares of Gritstone bio (a derivative holding)SEC Form 422 June 2022Stock Option (Right to Buy) · traded 17 June 2022 · filed 22 June 2022
- was granted 53,700 shares of Oric Pharmaceuticals (a derivative holding)SEC Form 417 June 2022Stock Option (right to buy) · traded 17 June 2022 · filed 17 June 2022
- was granted 19,500 shares of PMV Pharmaceuticals (a derivative holding)SEC Form 46 June 2022Stock Option (right to buy) · traded 2 June 2022 · filed 6 June 2022
- was granted 19,000 shares of Gritstone bio (a derivative holding)SEC Form 419 November 2021Stock Option (Right to Buy) · traded 18 June 2021 · filed 19 November 2021
- ▼ sold on the open market 706 shares of Oric PharmaceuticalsSEC Form 416 September 2021Common Stock · traded 14 September 2021 · filed 16 September 2021
- ▼ sold on the open market 682 shares of Oric PharmaceuticalsSEC Form 416 September 2021Common Stock · traded 15 September 2021 · filed 16 September 2021
- ▼ sold on the open market 479 shares of Oric PharmaceuticalsSEC Form 414 September 2021Common Stock · traded 10 September 2021 · filed 14 September 2021
- ▼ sold on the open market 601 shares of Oric PharmaceuticalsSEC Form 414 September 2021Common Stock · traded 13 September 2021 · filed 14 September 2021
- ▼ sold on the open market 1,086 shares of Oric PharmaceuticalsSEC Form 49 September 2021Common Stock · traded 7 September 2021 · filed 9 September 2021
- was granted 5,781 shares of PMV Pharmaceuticals (a derivative holding)SEC Form 423 July 2021Stock Option (right to buy) · traded 12 May 2021 · filed 23 July 2021
- was granted 16,625 shares of Oric Pharmaceuticals (a derivative holding)SEC Form 417 June 2021Stock Option (right to buy) · traded 16 June 2021 · filed 17 June 2021
- was granted 16,333 shares of PMV Pharmaceuticals (a derivative holding)SEC Form 49 June 2021Stock Option (right to buy) · traded 2 June 2021 · filed 9 June 2021
- was granted 14,800 shares of Yumanity Therapeutics (a derivative holding)SEC Form 44 June 2021Stock Option (Right to Buy) · traded 2 June 2021 · filed 4 June 2021
- exercised options over 1,950 shares of PMV PharmaceuticalsSEC Form 42 June 2021Common Stock · traded 1 June 2021 · filed 2 June 2021
- ▼ sold on the open market 1,392 shares of PMV PharmaceuticalsSEC Form 42 June 2021Common Stock · traded 1 June 2021 · filed 2 June 2021
- ▼ sold on the open market 553 shares of PMV PharmaceuticalsSEC Form 42 June 2021Common Stock · traded 1 June 2021 · filed 2 June 2021
- ▼ sold on the open market 5 shares of PMV PharmaceuticalsSEC Form 42 June 2021Common Stock · traded 1 June 2021 · filed 2 June 2021
- exercised options over 975 shares of PMV PharmaceuticalsSEC Form 42 June 2021Common Stock · traded 1 June 2021 · filed 2 June 2021
- ▼ sold on the open market 743 shares of PMV PharmaceuticalsSEC Form 42 June 2021Common Stock · traded 1 June 2021 · filed 2 June 2021
- ▼ sold on the open market 230 shares of PMV PharmaceuticalsSEC Form 42 June 2021Common Stock · traded 1 June 2021 · filed 2 June 2021
- ▼ sold on the open market 2 shares of PMV PharmaceuticalsSEC Form 42 June 2021Common Stock · traded 1 June 2021 · filed 2 June 2021
- exercised options over 975 shares of PMV PharmaceuticalsSEC Form 42 June 2021Common Stock · traded 1 June 2021 · filed 2 June 2021
- ▼ sold on the open market 764 shares of PMV PharmaceuticalsSEC Form 42 June 2021Common Stock · traded 1 June 2021 · filed 2 June 2021
- ▼ sold on the open market 209 shares of PMV PharmaceuticalsSEC Form 42 June 2021Common Stock · traded 1 June 2021 · filed 2 June 2021
- ▼ sold on the open market 2 shares of PMV PharmaceuticalsSEC Form 42 June 2021Common Stock · traded 1 June 2021 · filed 2 June 2021
- exercised options over 1,950 shares of PMV Pharmaceuticals (a derivative holding)SEC Form 42 June 2021Stock Option (right to buy) · traded 1 June 2021 · filed 2 June 2021
- exercised options over 975 shares of PMV Pharmaceuticals (a derivative holding)SEC Form 42 June 2021Stock Option (right to buy) · traded 1 June 2021 · filed 2 June 2021
- exercised options over 975 shares of PMV Pharmaceuticals (a derivative holding)SEC Form 42 June 2021Stock Option (right to buy) · traded 1 June 2021 · filed 2 June 2021
- was granted 16,500 shares of Metacrine (a derivative holding)SEC Form 425 May 2021Stock Option (right to buy) · traded 24 May 2021 · filed 25 May 2021
- ▼ sold on the open market 700 shares of Oric PharmaceuticalsSEC Form 424 May 2021Common Stock · traded 20 May 2021 · filed 24 May 2021
- ▼ sold on the open market 600 shares of Oric PharmaceuticalsSEC Form 424 May 2021Common Stock · traded 21 May 2021 · filed 24 May 2021
- ▼ sold on the open market 100 shares of Oric PharmaceuticalsSEC Form 424 May 2021Common Stock · traded 24 May 2021 · filed 24 May 2021
- ▼ sold on the open market 3,215 shares of Oric PharmaceuticalsSEC Form 418 May 2021Common Stock · traded 14 May 2021 · filed 18 May 2021
- ▼ sold on the open market 498 shares of Oric PharmaceuticalsSEC Form 418 May 2021Common Stock · traded 17 May 2021 · filed 18 May 2021
- ▼ sold on the open market 2,161 shares of Oric PharmaceuticalsSEC Form 418 May 2021Common Stock · traded 18 May 2021 · filed 18 May 2021
- ▼ sold on the open market 100 shares of Oric PharmaceuticalsSEC Form 413 May 2021Common Stock · traded 11 May 2021 · filed 13 May 2021
- ▼ sold on the open market 100 shares of Oric PharmaceuticalsSEC Form 430 April 2021Common Stock · traded 28 April 2021 · filed 30 April 2021
- ▼ sold on the open market 100 shares of Oric PharmaceuticalsSEC Form 430 April 2021Common Stock · traded 30 April 2021 · filed 30 April 2021
- ▼ sold on the open market 100 shares of Oric PharmaceuticalsSEC Form 45 April 2021Common Stock · traded 1 April 2021 · filed 5 April 2021
- was granted 1,959 shares of Yumanity TherapeuticsSEC Form 43 February 2021Common Stock · traded 1 February 2021 · filed 3 February 2021
- was granted 5,271 shares of Yumanity Therapeutics (a derivative holding)SEC Form 428 December 2020Stock Option (Right to Buy) · traded 22 December 2020 · filed 28 December 2020
- was granted 6,158 shares of Yumanity TherapeuticsSEC Form 428 December 2020Common Stock · traded 22 December 2020 · filed 28 December 2020
- was granted 45,332 shares of PMV Pharmaceuticals (a derivative holding)SEC Form 412 November 2020Stock Option (right to buy) · traded 11 November 2020 · filed 12 November 2020
- was granted 12,500 shares of Gritstone Oncology (a derivative holding)SEC Form 422 June 2020Stock Option (Right to Buy) · traded 18 June 2020 · filed 22 June 2020
- converted 62,500 shares of Oric Pharmaceuticals (a derivative holding)SEC Form 428 April 2020Series A Preferred Stock · traded 28 April 2020 · filed 28 April 2020
- converted 62,500 shares of Oric PharmaceuticalsSEC Form 428 April 2020Common Stock · traded 28 April 2020 · filed 28 April 2020
- was granted 16,625 shares of Oric Pharmaceuticals (a derivative holding)SEC Form 427 April 2020Stock Option (right to buy) · traded 23 April 2020 · filed 27 April 2020
Positions come from the unitedstates/congress-legislators roster, the Office of Government Ethics and the SEC’s Form 4 index. Every disclosed line names its own source and links the document the government published; we print what the filing says and never a price we did not read from it. Headlines and links come from the GDELT Global Knowledge Graph — the story stays with the publisher. The portrait, where we have one, is the public-domain Congressional Bioguide photograph.